Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"antibiotic treatment"

Slides: 1–12 of 12
Add to tray Remove from tray

Outline of this CME Activity

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: antibiotic treatment | diagnostic assays | prevention | recurrence | overview
Add to tray Remove from tray

Overview: Methods

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: analysis | data sources | literature | methods | overview
Add to tray Remove from tray

Overview: Results for Treatment of CDI with Standard Antibiotics

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: antibiotics | fidaxomicin | results | treatment | vancomycin | overview
Add to tray Remove from tray

Introduction: Current State of the Research on Antibiotic Therapy for CDI

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: C. difficile Infection (CDI) | FDA-approved antibiotics | metronidazole | oral vancomycin | recurrence | antibiotic therapy
Add to tray Remove from tray

Comparative Effectiveness of Standard Antibiotic Treatment for CDI

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: antibiotic treatment | C. difficile Infection (CDI) | FDA-approved antibiotics | organism strain
Add to tray Remove from tray

Comparative Effectiveness of Standard Antibiotic Treatment for CDI

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: C. difficile Infection (CDI) | initial cure rate | non-North American Pulsed Field type 1 strain | recurrence rates | antibiotic treatment
Add to tray Remove from tray

Comparative Effectiveness Results for Treatment of CDI With Antibiotics + Adjunctive Therapy

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: adjunctive therapy | antibiotics | C. difficile infection (CDI) | Lactobacillus plantarum | probiotics | Sacchromyces spp. | results
Add to tray Remove from tray

What To Discuss With Your Patients

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: patients | risk factors | prevention | antibiotic treatment | nonstandard interventions
Add to tray Remove from tray

Introduction

Presentation: Exposure Definition and Measurement in Observational Comparative Effectiveness Research
Keywords: background | exposure definition | exposure measurement
Add to tray Remove from tray

Background: The Need for Biomarkers To Guide Antibiotic Therapy for Bacterial Infections

Presentation: Procalcitonin-Guided Antibiotic Therapy
Keywords: antibiotic therapy | bacterial infection | biomarkers | procalcitonin | background
Add to tray Remove from tray

Applicability of the Findings of This Review

Presentation: Procalcitonin-Guided Antibiotic Therapy
Keywords: applicability | clinical practice | bacterial infection | procalcitonin | antibiotic therapy | patient populations | settings
Key Questions (I). KQ 1: In patients with cystic fibrosis, does treatment with rhGH as an adjuvant to usual care improve intermediate outcomes, including pulmonary function (FEV percent and FEV1 absolute value), growth (height, weight, lean body mass, protein turnover), exercise tolerance, and bone mineralization, compared with usual care alone? KQ 2: In patients with cystic fibrosis, does treatment with rhGH as an adjuvant to usual care improve health outcomes, including frequency of required intravenous antibiotic treatments, frequency of hospitalization, quality of life, bone fracture or development of osteoporosis/osteopenia, or mortality, compared with usual care alone? KQ 3: In patients with cystic fibrosis, what is the strength of evidence that intermediate outcomes of pulmonary function, growth, and bone mineralization are associated with improvements in health outcomes of quality of life, bone fracture or development of osteoporosis/osteopenia, or mortality? KQ 4: In patients with cystic fibrosis, what is the frequency of nonmalignant serious adverse effects resulting from treatment with rhGH? Adverse effects of interest include, but are not limited to: glucose intolerance, diabetes, and hypoglycemia.
Add to tray Remove from tray

Key Questions (I)

Presentation: Topic Refinement
Keywords: key question | PICOTS framework | analytic framework | health outcomes
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364